Novel potent metallocenes against liver stage malaria

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1564-1570

  Matos, Joana ^a   Da Cruz, Filipa P ^b   Cabrita, Élia ^c   Gut, Jiri ^d   Nogueira, Fátima ^c   Do Rosário, Virgílio E ^c   Moreira, Rui ^e   Rosenthal, Philip J ^d   Prudêncio, Miguel ^b   Gomes, Paula ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; FERROCENE DERIVATIVE; PRIMACENE; PRIMAQUINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOPHELES STEPHENSI; ANTIMALARIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE TRANSMISSION; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER STAGE MALARIA; MALARIA; MOUSE; NONHUMAN; PLASMODIUM BERGHEI; PRIORITY JOURNAL; SCHIZONT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIMALARIALS; ERYTHROCYTES; FERROUS COMPOUNDS; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HUMANS; INHIBITORY CONCENTRATION 50; LIVER; MALARIA; MICE; MICE, INBRED BALB C; OOCYSTS; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PRIMAQUINE; SPOROZOITES;

EID: 84857165822     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05345-11     Document Type: Article

References (34)

1. Alexandre MA, et al. 2010. Severe Plasmodium vivax malaria, Brazilian Amazon. Emerg. Infect. Dis. 16:1611-1614.
2. Araújo MJ, et al. 2005. Imidazolidin-4-ones of primaquine as novel transmission-blocking antimalarials. J. Med. Chem. 48:888-892. (Pubitemid 40209112)
3. Baird JK. 2009. Resistance to therapies for infection by Plasmodium vivax. Clin. Microbiol. Rev. 22:508-534.
4. Blackie MAL, et al. 2003. Synthesis and antimalarial activity in vitro of new heterobimetallic complexes: Rh and Au derivatives of chloroquine and a series of ferrocenyl-4-amino-7-chloroquinolines. J. Organomet. Chem. 688:144-152.
5. Burrows JN, Chibale K, Wells TNC. 2011. The state of the art in antimalarial drug discovery and development. Curr. Top. Med. Chem. 11:1226-1254.
6. Charton M. 1975. Steric effects. I. Esterification and acid-catalyzed hydrolysis of esters. J. Am. Chem. Soc. 97:1552-1556.
7. Daher W, et al. 2006. Assessment of Plasmodium falciparum resistance to ferroquine (SSR97193) in field isolates and in W2 strain under pressure. Malar. J. 5:11.
8. Dembele L, et al. 2011. Towards an in vitro model of Plasmodium hypnozoites suitable for drug discovery. PLoS One 6:e18162.
9. Dubar F, et al. 2009. Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach. J. Med. Chem. 52:7954-7957.
10. Dubar F, Khalife J, Brocard J, Dive D, Biot C. 2008. Ferroquine, an ingenious antimalarial drug - thoughts on the mechanism of action. Molecules 13:2900-2907.
11. Flower B, Armstrong-James D, Dance C, Bremner F, Doherty T. 2011. Blind, breathless, and paralysed from benign malaria. Lancet 377:438.
12. Galinski MR, Barnwell JW. 2008. Plasmodium vivax: who cares? Malar. J. 7(Suppl 1):S9.
13. Gleeson MP. 2008. Generation of a set of simple, interpretable ADMET rules of thumb. J. Med. Chem. 51:817-834. (Pubitemid 351304691)
14. Guerra CA, et al. 2010. The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl. Trop. Dis. 4:e774.
15. Kaur K, et al. 2007. Synthesis, antimalarial, antileishmanial, antimicrobial, cytotoxicity, and methemoglobin (MetHB) formation activities of new 8-aminoquinolines. Bioorg. Med. Chem. 15:915-930. (Pubitemid 44880711)
16. Kaur K, Jain M, Reddy RP, Jain R. 2010. Quinolines and structurally related heterocycles as antimalarials. Eur. J. Med. Chem. 45:3245-3264.
17. Kaur K, et al. 2011. Synthesis, antiprotozoal, antimicrobial, β-hematin inhibition, cytotoxicity and methemoglobin (MetHb) formation activities of bis(8-aminoquinolines). Bioorg. Med. Chem. 19:197-210.
18. Markus MB. 2011. The hypnozoite concept, with particular reference to malaria. Parasitol. Res. 108:247-252.
19. Matos J, et al. 2010. Primacenes: novel non-cytotoxic primaquine ferrocene-conjugates with anti-Pneumocystis carinii activity. Medchemcomm 1:199-201.
20. McChesney JD. 1981. Considerations about the structure-activity relationships of 8-aminoquinoline antimalarial drugs. Bull. World Health Organ. 59:459-462. (Pubitemid 11024769)
21. Mendis K, Sina BJ, Marchesini P, Carter R. 2001. The neglected burden of Plasmodium vivax malaria. Am. J. Trop. Med. Hyg. 64:97-106. (Pubitemid 32552576)
22. Moon MS, Richie JP, Isom HC. 2010. Iron potentiates acetaminophen-induced oxidative stress and mitochondrial dysfunction in cultured mouse hepatocytes. Toxicol. Sci. 118:119-127.
23. Mueller I, et al. 2009. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect. Dis. 9:555-566.
24. Na-Bangchang K, Ruengweerayut R, Mahamad P, Ruengweerayut K, Chaijaroenkul W. 2010. Declining in efficacy of a three-day combination regimen of mefloquine-artesunate in a multi-drug resistance area along the Thai-Myanmar border. Malar. J. 9:273.
25. Nodiff EA, Chaterjee S, Mussalam HA. 1991. Antimalarial activity of the 8-aminoquinolines. Prog. Med. Chem. 28:1-40.
26. Philip A, Kepler JA, Johnson BH, Carroll FI. 1988. Peptide derivatives of primaquine as potential antimalarial agents. J. Med. Chem. 31:870-874. (Pubitemid 18097113)
27. Ploemen IHJ, et al. 2009. Visualization and quantitative analysis of the rodent malaria liver stage by real time imaging. PLoS One 4:e7881.
28. Rosenberg R. 2007. Plasmodium vivax in Africa: hidden in plain sight? Trends Parasitol. 23:193-196. (Pubitemid 46618122)
29. Shiraki H, et al. 2011. Antimalarial activity of novel 5-aryl-8-aminoquinoline derivatives. J. Med. Chem. 54:131-142.
30. Vale N, Moreira R, Gomes P. 2009. Primaquine revisited six decades after its discovery. Eur. J. Med. Chem. 44:937-953.
31. Vale N, et al. 2009. Imidazoquines as antimalarial and antipneumocystis agents. J. Med. Chem. 52:7800-7807.
32. Van den Eede P, et al. 2011. Plasmodium vivax sub-patent infections after radical treatment are common in Peruvian patients: results of a 1-year prospective cohort study. PLoS One 6:e16257.
33. Wells TNC, Burrows JN, Baird JK. 2010. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trends Parasitol. 26:145-151.
34. White NJ. 2004. Antimalarial drug resistance. J. Clin. Invest. 113:1084-1092. (Pubitemid 38544090)